Mylan Launches Generic Version of Aciphex® Tablets

PITTSBURGH, Nov. 11, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Rabeprazole Sodium Delayed-release Tablets, 20 mg. Rabeprazole Sodium Delayed-release Tablets are the generic version of Eisai Corporation's Aciphex® Tablets, and are indicated for short-term treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease, and for short-term treatment in the healing and symptomatic relief of duodenal ulcers. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Aciphex Tablets, 20 mg, had U.S. sales of approximately $830.1 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com